In 2017, we received funding from CIHR’s Partnership for Health Systems Improvement initiative for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) collaboration. This collaboration will develop a framework for the generation and use of Real World Evidence (RWE) for cancer drug funding decisions in Canada.
The CanREValue collaboration brings together key stakeholders including ARCC, CADTH/ pCODR, CAPCA, Health Canada, INESSS, Ministries/departments of Health, pCPA, PMPRB, and provincial cancer agencies from across Canada. By providing a platform for stakeholders to discuss their needs and existing evidence gaps, the CanREValue collaboration will enable knowledge exchange, and address policy relevant research questions.
Contact us: CanREValue@cc-arcc.ca
https://cc-arcc.ca/wp-content/uploads/2018/07/CanRevalue-logo.jpg
237
872
Rebecca Mercer
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png
Rebecca Mercer2021-10-26 10:36:302021-10-26 10:37:01New Publication: Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group
https://cc-arcc.ca/wp-content/uploads/2018/07/CanRevalue-logo.jpg
237
872
Rebecca Mercer
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png
Rebecca Mercer2021-06-22 09:50:262021-06-22 09:50:26New Publication: Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces
https://cc-arcc.ca/wp-content/uploads/2018/07/CanRevalue-logo.jpg
237
872
Rebecca Mercer
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png
Rebecca Mercer2021-03-23 10:51:052021-03-23 11:04:14Updated CanREValue Interim Methods Report + Response to Stakeholder Feedback now available!
https://cc-arcc.ca/wp-content/uploads/2018/07/CanRevalue-logo.jpg
237
872
Rebecca Mercer
https://cc-arcc.ca/wp-content/uploads/2014/11/ARCC_Logo_Horizonta2l.png
Rebecca Mercer2020-10-30 11:19:112020-10-30 11:45:44Responses to Stakeholder Feedback re: CanREValue Interim Policy Report now available!
Patient perspectives of Value Frameworks used to Guide Oncology Treatment DecisionsMay 1, 2021 - 12:27 pmUnderstanding British Columbia cancer patients’ experiences with virtual health before and during the COVID-19 pandemicMay 1, 2021 - 11:53 amBenchmarking End of Life Quality Indicators by Tumor Type & Describing models of palliative care across CanadaApril 1, 2021 - 8:56 amEvaluation of the systemic cancer therapy volume-outcome association: a population-based study to inform the optimal provincial organization and delivery of systemic cancer therapyFebruary 1, 2021 - 12:20 pm
New Publication: Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) CollaborationMarch 28, 2023 - 1:56 pm
Associate or Full Professor (Tenure Track), Gerald Bronfman Department of Oncology, Division of Medical OncologyMarch 7, 2023 - 12:06 pm
CAHSPR is seeking the 2023 Article of the YearFebruary 1, 2023 - 7:41 am
CADTH Recognition Awards – Nominations Now Open!January 27, 2023 - 2:55 pm